

References

I-34

1. National Comprehensive Cancer Network® (NCCN). Ipilimumab. Drugs and Biologics Compendium. 2024.
2. Yervoy (ipilimumab) injection, for intravenous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised.02/2023.
3. Micromedex DrugDex Compendium®. 2024. Ipilimumab.
4. Clinical Pharmacology™ Compendium.2024. Tampa FL: Gold Standard, Inc. Ipilimumab.
5. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profiles of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35(34):3815-3826.
6. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology.2018;36(8):773-779.
7. Ipilimumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
8. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort. J Thorac Oncol.2020;15(5):426-435.
9. Larkin J, Chiarion-Sileni V, Gonazlez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med.2019;381:1535-1546.
- 10.Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093-2104.
- 11.Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended

follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol.* 2019;20(10):1370-1385.

12. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(2):198-211
13. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med.* 2022;386(5):449-462.